infectious-diseases-endocrinology-2019-posters-abstracts

4 / 20

Page 38
Notes:
conferenceseries.com
Volume 7 Journal of Infectious Diseases & Therapy Infectious Diseases & Endocrinology 2019
February 27-28, 2019
February 27-28, 2019 Tokyo, Japan
Infectious Diseases, Diabetes and Endocrinology
Global Experts Meeting on
Hanieh Entezari, J Infect Dis Ther 2019, Volume 7
DOI: 10.4172/2332-0877-C2-063
Does diabetes mellitus cause CYP2C19 phenoconversion? Evaluation of metformin and cinnamon
effects on CYP2C19 activity in type 2 diabetic rats
Hanieh Entezari
Tehran University of Medical Sciences, Iran
Introduction: Change in the metabolism of drugs is very likely in diabetes mellitus. This study assessed the changes in
enzymatic activity of CYP450 2C19 in liver by using omeprazole as probe in the animal model of type II diabetes, before and
after administration of metformin and cinnamon.
Method: 28 male Wistar rats randomly divided into 7 groups. 7 days after induction of diabetes type 2, test groups received
metformin, cinnamon and metformin plus cinnamon daily for 14 days. In day 21, rats were subjected to liver perfusion by
Krebs-Henselit buffer containing omeprazole as CYP2C19 probe. Perfusate samples were analyzed by HPLC-UV in order to
evaluate CYP2C19 activity.
Result: The average metabolic ratio of omeprazole was changed from 0.091±0.005 in the control group to 0.054±0.005 in the
untreated diabetic group (p-value=0.003). This average was increased inordinately to 0.218±0.036 in the treated group with
metformin. Interestingly, administration of cinnamon with metformin in diabetic rats caused the enzyme activity to return
(0.085±0.002) to the observed levels (0.091±0.005) in control group (p-value=0.26).
Conclusion: The results of the study showed that despite the suppression of CYP2C19 enzyme activity in type 2 diabetic
rats, administration of metformin can severely increase the enzyme activity. Surprisingly, simultaneous use of cinnamon and
metformin can modulate the function of CYP2C19 to the observed level in control group and make it more predictable to treat
diabetes mellitus and fate of other drugs that metabolize by this enzyme.
Biography
Hanieh Entezari has completed PhD from Tehran University of Medical Sciences. Her current position is pharmacist in the Sina Hospital. She has done some
research in bio-pharmacy and pharmacognosy lab. She has participated in PCS 2nd Global Diabetes Conference (GDC-2017), Prague, Czech Republic and 14th
Iranian Pharmaceutical Sciences Congress (IPSC), Tehran University of Medical Sciences, School of Pharmacy, Iran (2016). She has experience in handling and
surgery of animal lab and can work with HPLC device.